BridgeBio Pharma, Inc. Q1 2026 Earnings Recap

Shares declined modestly by 1.0% following a Q1 report that showed ongoing commercial momentum for Attruby but lacked near-term clinical catalysts or definitive upside in competitive positioning, reflecting investor caution amid a cautious outlook.

Key Takeaways

• Attruby net product revenue reached $180.6 million in the U.S., up 24% sequentially and 392% year-over-year, supporting its trajectory toward blockbuster status in 2026.
• The company highlighted progress in clinical differentiation, with emerging real-world evidence suggesting Attruby’s superiority over Pfizer’s tafamidis in certain outcomes, including a 43% reduction in diuretic intensification.
• Total new patient starts in the category exceeded 6,100 this quarter, with BridgeBio positioned as the clear second by volume, though Pfizer maintains the front-line lead.
• Near-term outlook remains cautious with no major clinical catalysts expected, although multiple first-in-class or best-in-class launches are in preparation.
• Management announced an immediate share buyback program aiming to capture long-term value amid the stock trading well below intrinsic valuation.